What’s going on with RDHL?
RedHill Biopharma Ltd. (RDHL) announced today that Medi-Cal, the California healthcare program Medicaid, has added Talicia to its list of contracted drugs for H. pylori processing, without prior authorization required.
Talicia’s coverage began for the two million FFS patients in Medi-Cal, California on October 1, 2021.
RDHL shares were down 1.91% to $ 4.61 on Wednesday morning.
What does this mean for RedHill Biopharma?
The addition of the Talicia Contractual Paid Drug List by Medi-Cal without prior authorization is a significant extension of coverage for California patients and continues to increase Talicia’s overall unrestricted coverage.
Talicia is the first and only FDA-approved rifabutin treatment for H. pylori infection, designed as a first-line option to treat the high resistance of H. pylori bacteria to standard treatments.
“The addition of Talicia by Medi-Cal without prior authorization is an important step in Talicia’s continued growth and we are delighted that it is being made available to Medi-Cal’s 2 million FFS,” said Rick Scruggs. , Commercial Director of RedHill.
“There is growing recognition that there is a need for effective first-line therapy against H. pylori infections that are not dependent on clarithromycin and that patients can tolerate well and adhere to for more than 14 days of treatment. Talicia meets these criteria. “
H. pylori is a bacterial infection which remains the most important known risk factor for gastric cancer. It is also a major risk factor for peptic ulcer disease.
RDHL has a fundamental ranking of 92. Find out what that means to you and get the rest of the ranking on RDHL!
Redhill Biopharma Ltd is a biopharmaceutical company specializing in gastrointestinal diseases. The company promotes gastrointestinal drugs including Movantik for opioid-induced constipation in adults, Talicia for the treatment of Helicobacter pylori infection in adults and Aemcolo for the treatment of traveler’s diarrhea. in adults. Its major late-stage clinical development programs include RHB-104 for Crohn’s disease; RHB-204, for pulmonary infections with non-tuberculous mycobacteria; RHB-102 (Bekinda) with positive results from a first phase 3 study for acute gastroenteritis and gastritis; Opaganib (Yeliva); RHB-106, an encapsulated bowel preparation and RHB-107, a phase 2 serine protease inhibitor targeting cancer and inflammatory gastrointestinal disease.